PDL BioPharma (NASDAQ:PDLI) Analyst Rating Consensus

PDL BioPharma (NASDAQ:PDLI) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 3 by 2 Brokerage Firm. 2 Brokerage Firms have advised hold.

PDL BioPharma (NASDAQ:PDLI) shares are expected to touch $3.75 in the short term. This short term price target has been shared by 2 analysts. However, the standard deviation of short term price estimate has been valued at 0.35. The target price could hit $4 on the higher end and $4 on the lower end.

PDL BioPharma (NASDAQ:PDLI) witnessed a decline in the market cap on Tuesday as its shares dropped 0.65% or 0.02 points. After the session commenced at $3.1, the stock reached the higher end at $3.1 while it hit a low of $2.97. With the volume soaring to 1,380,886 shares, the last trade was called at $3.04. The company has a 52-week high of $6.75. The company has a market cap of $502 million and there are 165,114,610 shares in outstanding. The 52-week low of the share price is $2.58.

PDL BioPharma, Inc. has lost 2.88% in the last five trading days and dropped 2.69% in the last 4 weeks. PDL BioPharma, Inc. has dropped 7.09% during the last 3-month period . Year-to-Date the stock performance stands at -11.46%.

PDL BioPharma, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. It is focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its stockholders. The Company receives royalties on a number of marketed products that use its technology and it has liscensed a number of humanized antibody products in late-stage clinical trials. As of December 31, 2014, the Company received royalties on sales of the ten humanized antibody products, which include Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *